Pharsight

Drugs that contain Capivasertib

1. Truqap patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10059714 ASTRAZENECA Protein kinase B inhibitors
Oct, 2028

(4 years from now)

US8101623 ASTRAZENECA Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
Mar, 2030

(5 years from now)

US9487525 ASTRAZENECA Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide
Apr, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809336 ASTRAZENECA Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors
Oct, 2025

(1 year, 5 months from now)

US9006430 ASTRAZENECA Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein
Oct, 2025

(1 year, 5 months from now)

US11760760 ASTRAZENECA Protein kinase B inhibitors
Oct, 2028

(4 years from now)

US10654855 ASTRAZENECA Protein kinase B inhibitors
Oct, 2028

(4 years from now)

US10039766 ASTRAZENECA Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide
Apr, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2028

NCE-1 date: 17 November, 2027

Market Authorisation Date: 16 November, 2023

Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...

Dosage: TABLET;ORAL

More Information on Dosage

TRUQAP family patents

Family Patents